Antithrombotic therapy in hypertension: a Cochrane Systematic review

Blood pressure measurement in atrial fibrillation: goodbye mercury?

“…16 Furthermore, hypertension is a major contributor to the risk of stroke and thromboembolism associated with this arrhythmia, and the presence of AF is one indication for antithrombotic therapy use in hypertension. 17 In a recent issue of the Journal of Human Hypertension, Jani et al 18 compared the accuracy of blood pressure readings using the manual mercury sphygmomanometer and Omron HEM -750 CP oscillometric device, in patients with AF and subjects with SR. Their results suggest that the Omron HEM -750 CP can be used in patients with AF, but stress the importance of multiple readings when using the mercury sphygmomanometer in the clinic settings.…”

Antiplatelet effects of Cyperus rotundus and its component (+)-nootkatone

“…Several studies reported that uncontrolled blood pressure is associated with thrombotic and atherosclerotic complications (Lip et al, 1997;Felmeden and Lip, 2005), and that the pathophysiological changes in high blood pressure are contributed to an intravascular microenvironment which promotes platelet aggregation and thrombus formation (Lip et al, 2001). Moreover, the increased platelet activity was found in patients suffering from vascular injury and hypertension (Felmeden and Lip, 2005).…”

“…Moreover, the increased platelet activity was found in patients suffering from vascular injury and hypertension (Felmeden and Lip, 2005). Hence, antiplatelet therapy has been supposed to be beneficial for patients with hypertension.…”

Towards improving the clinical assessment and management of human hypertension: an overview from this Journal

“…In one study, for example, statin use by hyperlipidaemic hypertensive patients was associated with a significant reduction in aortic stiffness without any marked effect on BP. 27 Aspirin therapy in hypertension has always attracted controversy, and a Cochrane systematic review 28 on this topic concluded that for primary prevention in patients with elevated BP, antiplatelet therapy cannot be recommended as the magnitude of benefit, a reduction in myocardial infarction, was negated by a harm of similar magnitude, with an increase in major haemorrhage. For secondary prevention in patients with elevated BP, antiplatelet therapy is recommended because the magnitude of the absolute benefit is many times greater.…”